Kavitha Ramchandran, MD
Medical Oncology · Stanford, CANPI 1407091820
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (35.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. AstraZeneca accounts for 64.1% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for medical oncology clinicians in CA, where the typical reported total is $4,042.
Across 7 payments — averaging $190.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$856
- Varian Medical Systems, Inc.$480
Across 12 payments — averaging $34,982 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Varian Medical Systems, Inc.$311K
- Siemens Medical Solutions USA, Inc.$109K
What the payments were for
- Consulting fees$48036%
- Speaking & faculty fees$40730%
- Travel & lodging$27420%
- Food & beverage$17613%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 6 | $856 |
| Varian Medical Systems, Inc. | 1 | $480 |
How this compares
$1,336 in reported general payments places this provider in the 35th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 17 | $278,760 |
| Pregabalin | 14 | $288 |
| Gabapentin | 15 | $258 |
| Mirtazapine | 14 | $178 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $856 | $278,76017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 379 medical oncology providers in California.
Other medical oncology in Stanford
- Ronald LevyStanford$475K
- Mark PegramStanford$374K
- Saad Munib Ahmed KhanStanford$262K
- Sandhya SrinivasStanford$220K
- Joel NealStanford$199K
- Gabriel MannisStanford$171K
- Lipika GoyalStanford$166K
- Melinda TelliStanford$137K
- Ranjana AdvaniStanford$113K
- Stephen SherwinSan Francisco$6.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.